The ENCIRCLE Trial (ENCIRCLE)
SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a prospective single-arm, multicenter study.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Camperdown, Australia, NSW2050
- Royal Prince Alfred Hospital
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- The Prince Charles Hospital
-
-
-
-
-
Toronto, Canada, M5B 1W8
- St. Michael's
-
Vancouver, Canada, V6E 1M7
- St. Pauls
-
-
Quebec
-
Québec, Quebec, Canada, G1V 0A6
- Laval University
-
-
-
-
-
Petah Tikva, Israel, 4941492
- Rabin Medical Center
-
-
-
-
-
Leiden, Netherlands, 2333 ZA
- Leiden University Medical Center
-
Rotterdam, Netherlands, 3015 CE
- Rotterdam Erasmus MC
-
-
-
-
-
London, United Kingdom, EC1A 7BE
- Saint Bartholomew's Medical Center
-
London, United Kingdom, SE1 7EH
- Saint Thomas Hospital
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Heart Center Hospital
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Banner University Medical Center
-
Phoenix, Arizona, United States, 85013
- Saint Josephs Hospital Medical Center Dignity Health
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Health
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, United States, 90017
- Good Samaritan Hospital
-
Los Angeles, California, United States, 90071
- Kaiser Sunset LA
-
San Francisco, California, United States, 94109
- California Pacific Medical Center
-
-
Colorado
-
Loveland, Colorado, United States, 80538
- UC Health Northern Colorado (Medical Center of the Rockies)
-
-
Florida
-
Gainesville, Florida, United States, 32605
- Cardiac & Vascular Institute Foundation
-
Jacksonville, Florida, United States, 32204
- Ascension St. Vincent's Hospital
-
Naples, Florida, United States, 34102
- Naples Community Hospital
-
Sarasota, Florida, United States, 34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University
-
Atlanta, Georgia, United States, 30309
- Piedmont Healthcare
-
-
Illinois
-
Glenview, Illinois, United States, 60026
- Northshore University Health System
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas
-
Wichita, Kansas, United States, 67226
- Cardiovascular Research Institute of Kansas (CRIOK)
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Our Lady of the Lake Regional Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- Medstar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
Saint Cloud, Minnesota, United States, 56303
- CentraCare
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Saint Luke's Kansas City
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Robert Wood Johnson University Hospital
-
-
New York
-
Buffalo, New York, United States, 14203
- University of Buffalo
-
New York, New York, United States, 10007
- Weill Cornell Medicine
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Novant Health and Vascular Institute
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
Cleveland, Ohio, United States, 44122
- Cleveland Clinic Foundation
-
Columbus, Ohio, United States, 43123
- Mount Carmel East Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Oklahoma Heart Hospital
-
Tulsa, Oklahoma, United States, 74104
- Oklahoma Heart Institute
-
-
Pennsylvania
-
Mechanicsburg, Pennsylvania, United States, 17050
- UPMC Heart and Vascular Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Saint Thomas Health
-
-
Texas
-
Austin, Texas, United States, 78705
- Austin Heart
-
Houston, Texas, United States, 77030
- UT Memorial Hermann
-
Houston, Texas, United States, 77004
- HCA Houston Healthcare Medical (SCRI)
-
-
Utah
-
Murray, Utah, United States, 84107
- Intermountain Medical Center
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Sentara Norfolk
-
Roanoke, Virginia, United States, 24014
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Seattle
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- MR ≥ 3+
- NYHA functional class ≥ II
- Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations.
- Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment.
- The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.
Exclusion Criteria:
- Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve
- Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve
- Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation
- Left ventricular ejection fraction <25%
- Severe right ventricular dysfunction
- Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months
- History of heart transplant
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- Active bacterial endocarditis within 180 days of the procedure
- Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
- Myocardial infarction within 30 days of the procedure
- Clinically significant untreated coronary artery disease requiring revascularization
- Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure
- Stroke or transient ischemic attack within 90 days of the procedure
- Irreversible, severe pulmonary hypertension
- Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use
- Renal insufficiency or receiving renal replacement therapy
- Liver disease
- Planned surgery within the next 12 months
- Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure
- Active infection requiring current antibiotic therapy
- Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states
- Refusal of blood products
- Female who is pregnant or lactating
- Estimated life expectancy <12 months due to non-cardiac conditions
- Participating in another investigational drug or device study that has not reached its primary endpoint
- Subject considered to be part of a vulnerable population
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TMVR - Main Cohort
Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR). |
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach. |
|
Experimental: TMVR - Failed TEER Registry
Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR. |
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach. |
|
Experimental: TMVR - MAC Registry
Subjects with mitral annular calcification (MAC) will have TMVR. |
During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Non-hierarchical composite of death and heart failure rehospitalization
Time Frame: 1 year
|
Number of subjects with death and/or heart failure rehospitalization |
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Improvement in NYHA functional class compared to baseline
Time Frame: 1 year
|
New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest. |
1 year
|
|
Improvement in KCCQ Overall Score compared to baseline
Time Frame: 1 year
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. |
1 year
|
|
Improvement in MR compared to baseline
Time Frame: 1 year
|
Number of subjects with improved MR compared to baseline |
1 year
|
|
Decrease in LVEDVi compared to baseline
Time Frame: 1 year
|
Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline |
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: John Webb, MD, St. Paul's Hospital
- Principal Investigator: Mayra Guerrero, MD, Mayo Clinic
- Principal Investigator: David Daniels, MD, California Pacific Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2018-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.